Insys Therapeutics reports positive preliminary data for allergy nasal spray

Shares in Insys Therapeutics (NSDQ:INSY) jumped yesterday after the company reported positive data for its investigational epinephrine nasal spray designed as a needle-free treatment for anaphylaxis.
In a 60-person pharmacokinetics study, early data show that the company’s intranasal formulation of epinephrine boasted similar bioavailability to epinephrine delivered via Mylan’s EpiPen auto-injector.
Get the full story at our sister site, Drug Delivery Business News.
The post Insys Therapeutics reports positive preliminary data for allergy nasal spray appeared first on MassDevice.

Source: Mass Device - June 15, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Wall Street Beat Insys Therapeutics Inc. Source Type: news